Orexo
15,04
SEK
-4,2 %
Mindre end 1K følgere
ORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
-4,2%
-15,32%
-14,06%
-5,88%
-1,05%
-7,96%
-26,27%
-70,1%
-83,28%
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Læs mereMarkedsværdi
522,05 mio. SEK
Aktieomsætning
188,22 t SEK
Omsætning
590 mio.
EBIT %
-23,78 %
P/E
-
Udbytteafkast, %
-
Finanskalender
6.5
2025
Delårsrapport Q1'25
8.5
2025
Generalforsamling '25
16.7
2025
Delårsrapport Q2'25
ViserAlle indholdstyper

Orexo, Audiocast with teleconference, Q4'24
Carnegie Access: Orexo: Solid numbers – Q4(24) initial comments
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Orexo Interim Report Q4 2024, incl. Full Year Report
Carnegie Access: Orexo: A somewhat better finish to a volatile year – Q4 preview
Invitation to presentation of Orexo´s Full Year Report 2024
Orexo converts future rights for OX-MPI to shares in Gesynta Pharma valued at SEK 19 million
Carnegie Access: Orexo: Positive OX640 read-out
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
Report from Orexo AB’s extraordinary general meeting, December 18 2024
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
Carnegie Commissioned Research: Orexo: A less cloudy day dawns as a settlement is struck
Orexo resolves Zubsolv US patent litigation with Sun Pharmaceutical Industries
Carnegie Commissioned Research: Orexo: Clouds overshadow the potential
Orexo and GAIA agree to terminate the partnership for Deprexis®
Notice of Extraordinary General Meeting in Orexo AB (publ)
Orexo's Nomination Committee proposes Dr. Friedrich von Bohlen und Halbach as a new member of the Board
